Vermorken J, Cervantes A, Morsing P, Johansson K, et al. A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer. Ann Oncol 2019;30 Suppl 4:iv36.
PMID: 32085133